Multiple myeloma trials in France

In France 92 Also abroad 703

92 trials · From ClinicalTrials.gov and EU CTIS (euclinicaltrials.eu), checked 11 November 2026. Ask the study team whether a trial fits you.

Phase 2/3Taking people
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Where
Caen Cedex 9, Dunkirk Cedex 1, Epagny Metz-tessy, Lille, Montpellier Cedex 5, Nantes, Paris, Pessac, Pierre-Bénite, Poitiers, Saint-Priest-en-Jarez, Toulouse Cedex 9, Tours, Vannes
Age
18 years and over
People
680 worldwide
Run by
AbbVie
See details and how to joinNCT07095452 · EU 2025-520897-21-00
Phase 2Enrolling by invitation
International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab
Where
Nantes
Age
18 years and over
People
70 worldwide
Run by
Sanofi
See details and how to joinNCT05669989
Phase 3Taking people
A Phase 3 Study Comparing Ramantamig plus Daratumumab Versus DVRd or DRd in Participants With NDMM for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy
Where
Lille, Marseille, Montpellier Cedex 5, Nancy Cedex, Nantes, Paris, Pessac, Pierre-Bénite, Poitiers, Saint-Cloud, Toulouse Cedex 9, Tours
Age
18 years and over
People
423 worldwide
Run by
Janssen Cilag International
See details and how to join2026-526654-14-01 · EU 2026-526654-14-01
Phase 3Taking people
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Where
Angers, La Roche-sur-Yon, Nantes, Rennes, Rouen
Age
18 years and over
People
63 worldwide
Run by
CSL Behring
See details and how to joinNCT07648264 · EU 2026-525626-38-00
Phase 1/2Taking people
Isatuximab in Combination With Novel Agents in RRMM - Master Protocol
Where
Lille, Nantes, Paris
Age
18 years and over
People
258 worldwide
Run by
Sanofi
See details and how to joinNCT04643002
Phase 3Not yet taking people in France
A trial to learn how well AZD0120 works and about its safety in adults with transplant eligible newly diagnosed multiple myeloma.
Where
Lille, Nantes, Paris, Paris Cedex 12, Toulouse Cedex 9
Age
18 years and over
People
249 worldwide
Run by
AstraZeneca AB
See details and how to join2026-525367-40-00 · EU 2026-525367-40-00
Phase 1/2Not yet taking people in France
A Multicenter Study of Belantamab Mafodotin and Mezigdomide in Patients With Relapsed Multiple Myeloma
Where
Amiens Cedex 1, Angers, Argenteuil Cedex, Bayonne, Bordeaux, Brest, Caen Cedex 9, Clermont-Ferrand, Dijon, Epagny Metz-tessy, Grenoble Cedex 9, Le Mans Cedex 9, Lille Cedex, Limoges, Nancy, Nantes, Nantes Cedex 2, Nice, Orleans Cedex 2, Paris, Paris Cedex 12, Paris Cedex 13, Pierre-Bénite, Poitiers, Rouen Cedex, Saint-Etienne, Strasbourg, Toulouse Cedex 9, Tours Cedex 9
Age
18 years and over
People
44
Run by
Centre Hospitalier Universitaire de Saint Etienne
See details and how to joinNCT07612787 · EU 2025-520976-25-00
Phase 3Taking people
A Clinical Trial to Evaluate Efficacy, Safety, and Pharmacokinetics of Gamunex in Participants With Secondary Antibody Deficiency Associated With Chronic Lymphocytic Leukemia, Multiple Myeloma, or Non-Hodgkin Lymphoma
Where
Brest, Nantes Cedex 2, Tours
Age
18 years and over
People
49 worldwide
Run by
Grifols Biologicals, LLC
See details and how to joinNCT07582432 · EU 2026-526803-31-00
No phaseNot yet taking people in France
Immunomonitoring and Predictive Biomarkers After CAR-T Cell Therapy in B-Cell Lymphoma and Multiple Myeloma
Where
Rouen
Age
18 years and over
People
45
Run by
Centre Henri Becquerel
See details and how to joinNCT07852377
Phase 3Taking people
Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients
Where
Amiens Cedex 1, Angers, Argenteuil Cedex, Avignon Cedex 9, Bayonne, Besançon, Blois Cedex, Bobigny Cedex, Bourg En Bresse, Brest, Caen, Chalon Sur Saone Cedex, Chambéry, Clamart, Clermont-Ferrand, Corbeil-Essonnes, Creteil, Dijon, Dunkirk Cedex 1, Epagny Metz-tessy, Grenoble Cedex 9, La Roche Sur Yon Cedex 9, Le Chesnay Rocquencourt, Le Coudray, Le Mans Cedex 9, Lille Cedex, Limoges Cedex 1, Lyon, Meaux, Metz Cedex 03, Mont-De-Marsan Cedex, Montivilliers, Montpellier Cedex 5, Mulhouse, Nantes, Nice, Nimes Cedex 9, Orleans Cedex 2, Paris, Périgueux, Perpignan Cedex, Pessac, Pierre-Bénite, Poitiers, Pontoise, Quimper Cedex, Reims Cedex, Rennes, Rouen, Saint-Brieuc, Saint-Denis, Saint-Priest-en-Jarez, Saint-Quentin, Strasbourg Cedex 2, Tarbes Cedex 9, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy, Vannes, Villejuif
Age
18 years to 69 years
People
824 worldwide
Run by
Intergroupe Francophone du Myelome
See details and how to joinNCT06918002 · EU 2024-516418-39-00
Phase 3Taking people
A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)
Where
Lille, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse
Age
18 years and over
People
508 worldwide
Run by
AstraZeneca
See details and how to joinNCT07391657
Phase 3Taking people
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Where
Amiens, Lyon, Montpellier, Nantes, Poitiers, Talence, Toulouse, Tours
Age
18 years and over
People
700 worldwide
Run by
Janssen Research & Development, LLC
See details and how to joinNCT07518186
Phase 2Taking people
Faecal Microbiota Transplantation After Allogeneic Stem Cell Transplantation
Where
Amiens, Angers, Besançon, Clermont-Ferrand, Grenoble, Lille, Limoges, Lyon, Nancy, Nantes, Nice, Paris, Pessac, Poitiers, Rouen, Saint-Etienne, Toulouse
Age
18 years and over
People
150
Run by
University Hospital, Clermont-Ferrand
See details and how to joinNCT04935684
No phaseTaking people
Comparison of the Effects of Apixaban on Thrombin Generation in Patients With de Novo Multiple Myeloma
Where
Saint-Etienne
Age
18 years and over
People
36
Run by
Centre Hospitalier Universitaire de Saint Etienne
See details and how to joinNCT06474182 · EU 2024-515329-27-00
Phase 2Taking people
Phase 2 Randomized, Double-blind, Placebo-controlled Study of Prophylactic Tocilizumab to Prevent Cytokine Release Syndrome in Relapsed/Refractory Multiple Myeloma
Where
Argenteuil Cedex, Bayonne, Grenoble Cedex 9, Le Mans Cedex 9, Nantes, Quimper Cedex
Age
18 years and over
People
123 worldwide
Run by
Janssen Cilag International
See details and how to join2025-524793-42-00 · EU 2025-524793-42-00
Phase 3Not yet taking people in France
A trial to learn how well AZD0120 works and about its safety in adults with newly diagnosed multiple myeloma
Where
Lille, Nantes, Paris, Poitiers, Toulouse Cedex 9
Age
18 years and over
People
234 worldwide
Run by
AstraZeneca AB
See details and how to join2025-524014-29-00 · EU 2025-524014-29-00
No phaseTaking people
RAT-HEMATO : Return to Work After Malignant Hemopathy
Where
Angers, Brest, Caen, Cholet, Montivilliers, Morlaix, Rennes, Rouen, Tours
Age
18 years to 55 years
People
264
Run by
University Hospital, Angers
See details and how to joinNCT06262789
No phaseTaking people
A Study of Clinical Outcomes in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Treated With T-cell Redirectors Outside of Clinical Trials
Where
Lille, Marseille, Nantes, Paris, Toulouse, Vandœuvre-lès-Nancy
Age
18 years and over
People
900 worldwide
Run by
Janssen-Cilag Ltd.
See details and how to joinNCT06285318
Phase 2Taking people
A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)
Where
Dunkirk Cedex 1, Nantes, Paris, Saint-Priest-en-Jarez
Age
18 years and over
People
200 worldwide
Run by
GlaxoSmithKline
See details and how to joinNCT07227311 · EU 2025-523117-28-00
Phase 3Taking people
A Study to Learn About the Study Medicine Elranatamab Alone and With Daratumumab in People With Multiple Myeloma Who Have Received Other Treatments
Where
Lille Cedex, Limoges Cedex 1, Nantes, Paris, Paris Cedex 12, Pierre-Bénite, Poitiers, Toulouse Cedex 9
Age
18 years and over
People
893 worldwide
Run by
Pfizer
See details and how to joinNCT05020236 · EU 2023-509208-14-00
Phase 3Taking people
MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)
Where
Bayonne, Créteil, Dunkerque, La Roche Sur Yon Cedex 9, Le Mans Cedex 9, Nantes, Nice, Paris, Pessac, Poitiers, Pontoise, Quimper Cedex, Toulouse Cedex 9, Tours, Vandoeuvre Les Nancy Cedex, Vannes
Age
18 years and over
People
492 worldwide
Run by
Pfizer
See details and how to joinNCT06152575 · EU 2023-507871-23-00
Phase 1Taking people
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies
Where
Pessac
People
7 worldwide
Run by
USWM Ct LLC
See details and how to join2024-513033-21-00 · EU 2024-513033-21-00
Phase 3Taking people
Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT
Where
Lille, Nantes, Paris, Poitiers, Toulouse
Age
18 years and over
People
750 worldwide
Run by
AstraZeneca
See details and how to joinNCT07764978
Phase 3Taking people
A trial to learn how well AZD0120 works and how safe it is in people with relapsed or refractory multiple myeloma.
Where
Lille Cedex, Nantes, Paris, Pierre-Bénite, Poitiers, Toulouse Cedex 9
Age
18 years and over
People
153 worldwide
Run by
AstraZeneca AB
See details and how to join2025-523285-25-00 · EU 2025-523285-25-00
Phase 2Taking people
A multi-center, open-label, phase 2 study of Elranatamab in patients with high-risk smoldering multiple myeloma
Where
La Roche Sur Yon Cedex 9, Montpellier Cedex 5, Nantes, Nice, Poitiers, Tours
Age
18 years and over
People
105 worldwide
Run by
European Myeloma Network B.V.
See details and how to join2023-505775-70-00 · EU 2023-505775-70-00